Login to Your Account

Mucosis BV, a Dutch company developing mucosal vaccines that can be applied needle-free via the nose or mouth, is rapidly advancing toward clinical studies that could pave the way for the arrival of broad-based and durable protection from respiratory syncytial virus (RSV).
Betting on the restorative power of young blood to reverse cognitive decline in Alzheimer's disease and other central nervous system disorders, Grifols SA is taking a 45 percent stake in Stanford University spinout Alkahest Inc.
Graybug Inc., a spinout of Johns Hopkins University's Wilmer Eye Institute that's developing an experimental microparticle drug for wet age-related macular degeneration, has closed a $1.74 million series A2 financing to help advance a preclinical drug and further prove its sustained-release technology.
More Newco News Headlines

Cast Your Vote

Has biotech’s bubble burst?: